Literature DB >> 11819819

Preparation of single chain variable fragment of MG(7) mAb by phage display technology.

Z C Yu1, J Ding, Y Z Nie, D M Fan, X Y Zhang.   

Abstract

AIM: To develop the single chain variable fragment of MG MG(7)murine anti-human gastric cancer monoclonal antibody using the phage display technology for obtaining a tumor-targeting mediator.
METHODS: mRNA was isolated from MG MG(7) producing murine hybridoma cell line and converted into cDNA. The variable fragments of heavy and light chain were amplified separately and assembled into ScFv with a specially constructed DNA linker by PCR. The ScFvs DNA was ligated into the phagmid vector pCANTAB5E and the ligated sample was transformed into competent E. Coli TG1. The transformed cells were infected with M13K07 helper phage to form MG MG(7) recombinant phage antibody library. The volume and recombinant rate of the library were evaluated by means of bacterial colony count and restriction analysis. After two rounds of panning with gastric cancer cell line KATO III of highly expressing MG(7)-binding antigen, the phage clones displaying ScFv of the antibody were selected by ELISA from the enriched phage clones. The antigen-binding affinity of the positive clone was detected by competition ELISA. HB2151 E. Coli was transfected with the positive phage clone demonstrated by competition ELISA for production of a soluble form of the MG(7) ScFv. ELISA assay was used to detect the antigen-binding affinity of the soluble MG(7) ScFv. Finally, the relative molecular mass of soluble MG(7) ScFv was measured by SDS-PAGE.
RESULTS: The V(H), V(L) and ScFv DNAs were about 340bp, 320bp and 750bp, respectively. The volume of the library was up to 2 X 10(6) and 8 of 11 random clones were recombinants. Two phage clones could strongly compete with the original MG(7) antibody for binding to the antigen expressed on KATO III cells. Within 2 strong positive phage clones, the soluble MG(7) ScFv from one clone was found to have the binding activity with KATO III cells. SDS-PAGE showed that the relative molecular weight of soluble MG(7) ScFv was 32.
CONCLUSION: The MG(7) ScFv was successfully produced by phage antibody technology, which may be useful for broadening the scope of application of the antibody.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11819819      PMCID: PMC4688663          DOI: 10.3748/wjg.v7.i4.510

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

1.  Selection of human anti-HAV McAb from a phage antibody library.

Authors:  Z Wan; H Wang; S Jiang
Journal:  Chin J Biotechnol       Date:  1998

2.  In vivo selection of sFv from phage display libraries.

Authors:  M Johns; A J George; M A Ritter
Journal:  J Immunol Methods       Date:  2000-05-26       Impact factor: 2.303

3.  Identification of a human epitope in hepatitis C virus (HCV) core protein using a molecularly cloned antibody repertoire from a non-symptomatic, anti-HCV-positive patient.

Authors:  V Barban; S Fraysse-Corgier; G Paranhos-Baccala; M Petit; C Manin; Y Berard; A M Prince; B Mandrand; P Meulien
Journal:  J Gen Virol       Date:  2000-02       Impact factor: 3.891

Review 4.  Generating improved single-chain Fv molecules for tumor targeting.

Authors:  G P Adams; R Schier
Journal:  J Immunol Methods       Date:  1999-12-10       Impact factor: 2.303

5.  Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx.

Authors:  S Mao; C Gao; C H Lo; P Wirsching; C H Wong; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

6.  Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice.

Authors:  H Romanczuk; C E Galer; J Zabner; G Barsomian; S C Wadsworth; C R O'Riordan
Journal:  Hum Gene Ther       Date:  1999-11-01       Impact factor: 5.695

7.  Gene therapy for human colorectal carcinoma using human CEA promoter contro led bacterial ADP-ribosylating toxin genes human CEA: PEA & DTA gene transfer.

Authors:  Guang-Wen Cao; Zhong-Tian Qi; Xin Pan; Xiao-Qin Zhang; Xiao-Hui Miao; Yan Feng; Xin-Hua Lu; Shigeki Kuriyama; Ping Du
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

8.  Human recombinant single-chain antibody fragments, specific for the hypervariable region 1 of hepatitis C virus, from immune phage-display libraries.

Authors:  W Zhai; J Davies; D Z Shang; S W Chan; J P Allain
Journal:  J Viral Hepat       Date:  1999-03       Impact factor: 3.728

9.  Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library.

Authors:  S A Desai; X Wang; E J Noronha; T Kageshita; S Ferrone
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

Review 10.  Clinical aspects and typing of platelet alloantigens.

Authors:  H Kroll; V Kiefel; S Santoso
Journal:  Vox Sang       Date:  1998       Impact factor: 2.144

View more
  4 in total

1.  Expression and bioactivity identification of soluble MG7 scFv.

Authors:  Zhao-Cai Yu; Jie Ding; Bo-Rong Pan; Dai-Ming Fan; Xue-Yong Zhang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

2.  Selection of a peptide mimicking neutralization epitope of hepatitis E virus with phage peptide display technology.

Authors:  Ying Gu; Jun Zhang; Ying-Bing Wang; Shao-Wei Li; Hai-Jie Yang; Wen-Xin Luo; Ning-Shao Xia
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

3.  Construction, expression and tumor targeting of a single-chain Fv against human colorectal carcinoma.

Authors:  Jin Fang; Hong-Bin Jin; Jin-Dan Song
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

4.  Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhimurium as carrier.

Authors:  Chang-Cun Guo; Jie Ding; Bo-Rong Pan; Zhao-Cai Yu; Quan-Li Han; Fan-Ping Meng; Na Liu; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.